Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

#SHOWBIZ: 'Not scared': 'The Office' star Lucy Davis shares incurable stage 4 cancer diagnosis

LONDON: British actress Lucy Davis, best known for her role as receptionist Dawn Tinsley in the original BBC comedy series The Office, has shared a heartfelt health update, revealing that she is living with an "incurable" stage four breast cancer diagnosis.

#SHOWBIZ: 'Not scared': 'The Office' star Lucy Davis shares incurable stage 4 cancer diagnosis

LONDON: Actress Lucy Davis, famed for her role as Dawn Tinsley in the BBC sitcom The Office, has announced she is battling stage four breast cancer. The 53-year-old shared her diagnosis on Instagram, stating that the cancer has spread to her spine, hip, and ribs. Despite no longer being eligible for chemotherapy, Davis remains optimistic, declaring, "I'm not scared of whatever comes next.

I'm at peace with it." She used her platform to encourage followers to prioritize health and seek medical advice for any concerns. Davis, known for her comedic timing, demonstrated a resilient spirit, joking about a wheelchair should she be needed. Despite the physical challenges, she remains committed to her career in acting, expressing gratitude for the "teachable moments" the cancer has provided.

Written by urgent.news from New Straits Times's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nst.com.my →

More in Health & Medicine

JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior…

  • JW Pharmaceutical's epaminurad (URC102) outperformed febuxostat in Phase 3 gout trial.
  • Epaminurad achieved 50.0% serum uric acid reduction vs. 38.3% for febuxostat 40mg.
  • Safety profiles were comparable with no drug-related deaths reported.